Antigen News and Research

RSS

Predictive model helps tailor PSMA therapy for prostate cancer patients

A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy organs before therapy begins.

31 May 2026

AI-powered atlas maps immune structures across multiple cancer types

In a new study published today in Science, researchers from The University of Texas MD Anderson Cancer Center developed a spatial atlas of specialized immune structures, called tertiary lymphoid structures (TLSs), across multiple cancer types.

28 May 2026

Tomato-soy juice curbs inflammation in obese adults

Drinking tomato-soy juice loaded with compounds shown in animal studies to promote health lowered pro-inflammatory proteins in healthy adults with obesity after four weeks, a new study found.

26 May 2026

Silica nanoparticles dampen early allergy signals in mouse mast cells

This in vitro study found that negatively charged SiO2 nanoparticles suppressed antigen-induced degranulation and activation-marker changes in IgE-sensitized mouse bone marrow-derived mast cells. By contrast, mTiO2 nanoparticles showed cytotoxic and pro-inflammatory effects, including enhanced DNP-induced IL-6 release, suggesting nanoparticle composition can shape early allergic immune responses.

24 May 2026

Immunoproteasome plays emerging role in diabetes and metabolic complications

A newly published review article highlights the emerging importance of the immunoproteasome in the development and progression of diabetes and its wide-ranging complications, offering fresh perspectives on future therapeutic strategies.

24 May 2026

New computational pipeline improves effectiveness of pan-Ebola neutralizing antibodies

A team led by Professor Wei Yang at the National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, has developed a computational-experimental pipeline that synergistically optimizes antibody framework regions (FR) and complementarity-determining regions (CDR).

24 May 2026

Internal mutations and microbes may drive a distinct subtype of oral cancer

A new study reveals that many oral cancers are no longer driven by traditional risk factors like smoking or Human papillomavirus infection.

22 May 2026

Mitochondrial checkpoint enables dendritic cells to activate T lymphocytes against viruses, tumors

A study led by researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has identified a mitochondrial "checkpoint" that enables dendritic cells to efficiently activate T lymphocytes against viruses and tumors.

22 May 2026

Combination therapy improves response rates for chronic hepatitis B patients

The optimal management strategy for adults with immune-tolerant (IT) chronic hepatitis B infection remains undefined. This study aimed to investigate the efficacy and predictive factors of a pegylated interferon (Peg-IFN)-based treatment strategy in IT patients with chronic HBV infection.

22 May 2026

New gene expression signature may guide immunotherapy for resistant prostate cancer patients

Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.

21 May 2026

New CA19-9 threshold improves pancreatic cancer risk prediction accuracy

A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels because of a genetic variation that impairs their ability to produce this biomarker.

21 May 2026

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

20 May 2026

Rerouting dead tumor debris enhances cancer immunotherapy outcomes

As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual cancer cells die, exposing their internal scaffolds.

20 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

New mRNA vaccine strategy dramatically amplifies cancer-fighting T cells

Engineers from the University of Houston, MIT and Harvard have developed a new mRNA-based strategy that dramatically amplifies the T-cell response to vaccines - an advance that could lead to far more powerful cancer vaccines and stronger protection against infectious diseases.

19 May 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

Multi-institutional trial explores new lifeline for advanced prostate patients

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited – and time matters. As the disease progresses, the window for effective, less intensive treatments begins to close.

15 May 2026

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026

Researchers develop pH and redox-sensitive systems to reduce immunotherapy toxicity

Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small subset of patients benefit. Many solid tumors remain "cold," characterized by poor immune cell infiltration and resistance to immune checkpoint blockade (ICB).

15 May 2026

PSA tests detect 30 percent more cancers but may cause overtreatment

Blood tests to detect potential signs of prostate cancer likely reduce the risk of dying from prostate cancer, an updated Cochrane review finds. This is a shift from the previous version of the review, which did not find sufficient evidence that screening reduced prostate cancer deaths.

15 May 2026